Johnson & Johnson Slides On Top-Line Miss, Disappointing Drug Sales, Soft Outlook
On the surface, key Dow component Johnson & Johnson reported strong earnings, with EPS of $1.58 coming stronger than the $1.56 consensus expectation, despite revenue of $1.81BN missing consensus of $18.28BN. Among the key notables in the earnings report was the company's announcement it was in a process to evaluate potential strategic options for the Johnson & Johnson Diabetes Care Companies, specifically LifeScan, Animas, and Calibra. Such option "may include the formation of operating partnerships, joint ventures or strategic alliances, a sale of the businesses."